Corrigendum to “The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII” [Mol Genet Metab 2020 Mar;129(3):219–227] (Molecular Genetics and Metabolism (2020) 129(3) (219–227), (S1096719219307851), (10.1016/j.ymgme.2020.01.003))

Raymond Y. Wang, José Francisco da Silva Franco, Jaime López-Valdez, Esmeralda Martins, Vernon Reid Sutton, Chester B. Whitley, Lin Zhang, Tricia Cimms, Deborah Marsden, Agnieszka Jurecka, Paul Harmatz

Research output: Contribution to journalComment/debate

Abstract

We would like to correct the clinicaltrials.gov study registration number mentioned in the manuscript in several areas: In the abstract, the NCT number mentioned and linked (NCT02377921) is incorrect. The sentence that reads “… completed a Phase 3, randomized, placebo-controlled, blind-start, single crossover study (UX003-CL301; NCT02377921) …” should instead read, “… completed a Phase 3, randomized, placebo-controlled, blind-start, single crossover study (UX003-CL301; NCT02230566) … The link to the corrected NCT number should point to: https://clinicaltrials.gov/ct2/show/NCT02230566 The authors would like to apologize for any inconvenience caused. DOI of original article: doi: https://doi.org/10.1016/j.ymgme.2020.01.003

Original languageEnglish (US)
JournalMolecular Genetics and Metabolism
DOIs
StateAccepted/In press - 2020

PubMed: MeSH publication types

  • Published Erratum

Fingerprint Dive into the research topics of 'Corrigendum to “The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII” [Mol Genet Metab 2020 Mar;129(3):219–227] (Molecular Genetics and Metabolism (2020) 129(3) (219–227), (S1096719219307851), (10.1016/j.ymgme.2020.01.003))'. Together they form a unique fingerprint.

  • Cite this